GlobeNewswire

Press Release Oncology Venture Plans Name Change to Allarity Therapeutics and Board Restructuring to Align with Current Company Strategy

Share

Hørsholm, Denmark (21 September 2020) – Oncology Venture A/S (“OV”) today announced that it will change its company name to Allarity Therapeutics (“Allarity” or the “Company”) and will significantly restructure its Board of Directors to align with the company’s current and long-term strategy. Both the proposed name change and appointment of new Board members are subject to approval of shareholders at the upcoming Extraordinary General Meeting (EGM) planned to be convened on 7 October 2020.

Following the proposed restructuring, Allarity’s Board of Directors will comprise five members, including existing Directors Mr. Steve Carchedi (CEO), Mr. Duncan Moore (Chairman), and Dr. Magnus Persson, and new members in both the U.S. and Scandinavia, including Mr. Søren Gade (a current member of European Parliament and former Minister of Defense in Denmark) and Ms. Gail Maderis (current CEO of Antiva Biosciences, Inc., Board member of Valitor, Inc., and former CEO of Five Prime Therapeutics, Inc.). New Board members will receive warrants in the Company as part of their compensation package.

The changes to the Company name and composition of its Board of Directors are part of a planned strategic shift towards commercialization for the U.S. oncology and financial markets, while the company maintains its roots and laboratory headquarters in Denmark, which continue to be directly overseen by Dr. Steen Knudsen, Chief Scientific Officer and Founder, and Mr. Thomas Jensen, Senior Vice President of Information Technologies and Founder. The Hørsholm, Denmark facility will serve as the Research & Development global headquarters for the company’s DRP® companion diagnostic platform. As part of this strategic shift, current Chief Financial Officer (CFO) Mr. Henrik Moltke will be departing the Company to pursue other opportunities. Mr. James G. Cullem, currently Senior Vice President of Corporate Development, will serve as interim CFO, while the Company conducts an immediate search for a U.S.-based, CFO with Nasdaq experience.

Steve Carchedi, CEO of the Company, noted “Our new company name, Allarity Therapeutics, better reflects our focus on developing promising new cancer therapeutics, together with DRP® companion diagnostics, to match cancer patients with the best therapeutic options for their particular cancers, thereby realizing the promise of personalized medicine. We are also very enthusiastic about the planned restructuring of our Board of Directors to strengthen the strategic oversight of the Company and support our Executive Team in achieving our goals. I am thrilled to have Gail Maderis and Søren Gade join our Board, as both will provide valuable connections for us related to international cancer drug development while further expanding the geographic footprint of our Board to both sides of the Atlantic.”   

Mr. Carchedi further commented, “I also want to thank Henrik for his leadership over the past year. He has been instrumental in adjusting our cost base, cleaning up our balance sheet, and successfully changing our financing strategy towards low-cost equity financing. Henrik’s departure is bittersweet for the Company, but will allow us to find a new CFO who is an ideal match for the many tasks ahead on our continued journey towards bringing healthcare therapies to market for the benefit of patients.”

Duncan Moore, Board Chairman of the Company, commented “We are grateful for the efforts and contributions of our prior Board members, Steen Knudsen, Carani Sanjeevi, and Frank Knudsen, as well as CFO Henrik Moltke, and we look forward to working alongside our new Board members, Gail Maderis and Søren Gade, to advance the Company’s mission to improve cancer patient care by realizing truly personalized medicine.”

About Allarity Therapeutics (Oncology Venture)
Allarity Therapeutics (Nasdaq First North Growth Market Stockholm: OV.ST) develops drugs for personalized treatment of cancer guided by its proprietary drug response predictor technology, the DRP® platform. The company has a mature portfolio of six drug candidates, including compounds in the pre-registration stage. The product portfolio includes: Stenoparib (2X-121), a PARP inhibitor in Phase 2 for ovarian cancer; Dovitinib, a pan-TKI in post-Phase 3  for renal cell carcinoma; IXEMPRA ® (Ixabepilone), a microtubulin inhibitor approved in the U.S. for the treatment of breast cancer;  LiPlaCis®, a liposomal formulation of cisplatin in Phase 2 trials for breast and prostate cancer;  2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer; and Irofulven, a DNA damaging agent in Phase 2 for prostate cancer.

About the Drug Response Predictor – DRP® Companion Diagnostic

Allarity uses its drug specific DRP® to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, the response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and prior clinical trial outcomes. DRP® is based on messenger RNA from the patient’s biopsies. DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in nearly 40 clinical studies that were examined, including an ongoing, prospective Phase 2 trial. The DRP® platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs.

Follow us on social media:
Facebook: https://www.facebook.com/oncologyventure/
LinkedIn: https://www.linkedin.com/company/oncology-venture/
Twitter: https://twitter.com/OncologyVenture

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of Allarity’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning Allarity’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. Allarity undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Media Contacts:
Europe:
            Henrik Moltke, CFO
            +45 22 44 54 04
            hm@oncologyventure.com

U.S.

            Mike Beyer
            Sam Brown Inc.
            +1 312-961-2502
            mikebeyer@sambrown.com

Certified Adviser:
Svensk Kapitalmarknadsgranskning AB, Email: ca@skmg.se. Tel: +46 11 32 30 732

This information is information that Allarity A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on September 21, 2020.

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Auriant Mining AB (publ.) publishes 9m 2020 operational update19.10.2020 17:45:00 CESTPress release

Highlights: • 9m 2020 total gold productionamounted to 755 kg (24,285 oz), compared to 481 kg (15,467 oz) in 9m 2019, an increase of 57%, or 274 kg (8,818 oz). Hard rock gold production at Tardan increased from 430 kg (13,812 oz) in 9m 2019 to 750 kg (24,112 oz) in 9m 2020, or by 75%; • 9m 2020 gold sales amounted to 757 kg (24,322 oz), compared to 426 kg (13,696 oz) in 9m 2019, an increase of 331 kg (10,642 oz), or 78%; • Volume of ore processed through the newly built CIL plant amounted to 291 thousand tonnes with an average grade of 2.77 g/t (total gold in processed ore – 806 kg); • The CIL plant was operating at projected throughput per working hour (>50 t/hour) and higher recovery rate (92.9%); • Heap leach operations were discontinued at the end of December, 2019; • Ore mined amounted to 274 thousand tonnes (18% less than in the same period of the previous year). Stripping volume in 9m 2020 was 684 thousand m3 (12% less than in 9m 2019); • The average grade in ore mined in 9m 202

Auriant Mining AB (publ.) publicerar verksamhetsuppdatering för 9 månader 202019.10.2020 17:45:00 CESTPressemelding

Viktiga händelser: • Den totala guldproduktionen under 9 månader 2020 uppgick till 755 kg (24 285 oz), jämfört med 481 kg (15 467 oz) under 9 månader 2019, en ökning med 57% eller 274 kg (8 818 oz). Malmbaserad guldproduktion vid Tardan ökade från 430 kg (13 812 oz) under 9 månader 2019 till 750 kg (24 112 oz) under 9 månader 2020 eller med 75%; • Guldförsäljning under 9 månader 2020 uppgick till 757 kg (24 322 oz), jämfört med 426 kg (13 696 oz) under 9 månader 2019, en ökning med 331 kg (10 642 oz) eller med 78%; • Volymen av malm som bearbetades genom den nybyggda CIL-anläggningen uppgick till 291 kt med en snitthalt om 2,77 g/t (guld i malmen totalt – 806 kg); • CIL-anläggningen var i drift med beräknad bearbetningskapacitet per arbetstimme (>50 ton/timme) och återvinningsgrad (92,9%); • Lakning på hög avbröts i slutet of december 2019; • Volymen för den brutna malmen uppgick till 274 kt (18% lägre än under samma period föregående år). Arbetsvolymen för avrymningen uppgick till 684

EVS Broadcast Equipment reports update of share buyback program19.10.2020 17:45:00 CESTPress release

Publication on Octobre 19, 2020, after market closing Regulated information – reporting share buyback EVS Broadcast Equipment S.A.: Euronext Brussels (EVS.BR), Bloomberg (EVS BB), Reuters (EVSB.BR) EVS reports update of share buyback program EVS Broadcast Equipment reports that the following transactions, conducted within the framework of the share buyback program announced on May 6, 2020, took place between October 12, 2020 and October 16, 2020. DateNumber of shares acquiredAverage price (EUR)Highest price (EUR)Lowest price (EUR)Total (EUR)12/10/20202,50014.058114.3013.88 35,145 13/10/20202,50014.076014.2213.94 35,190 14/10/20202,50013.825214.0013.70 34,563 15/10/20202,50013.552013.6013.52 33,880 16/10/20202,25213.402113.5013.30 30,182 Total12,252 13.7904 14.30 13.30 168,960 As of October 16, 2020, and since the start of the buyback program, EVS has bought 302,916 shares at an average price of EUR 15,0557, representing in total EUR 4,560,617. After aforementioned transactions the tota

CONDITIONS FOR THE RIKSBANK´S PURCHASES OF COMMERCIAL PAPER19.10.2020 16:20:00 CESTPress release

Complete terms and conditions can be retrieved at http://www.riksbank.se https://www.riksbank.se/sv/penningpolitik/penningpolitiska-instrument/kop-av-foretagscertifikat/ Bid procedure on 21 October 2020 Certificate:Commercial paper issued in SEK by non-financial companies with their registered office in Sweden and with a remaining maturity of up to six months on the Bid date, i.e. with the maturity date on 21 April 2021 at the latest. Delivery may not be made in commercial paper purchased by the Counterparty from the issuer less than one week prior to the date for announcing the Special terms, i.e. the purchase may not have been made after 12 October 2020.Bids:Counterparties may make one bid per Credit rating class and maturity class. Bids are made to tel 08-696 69 70 and confirmed by e-mail to EOL@riksbank.se.Bid date:Wednesday 21 October 2020Bid time:0900-0930 hours (CEST) on the Bid dateRequested volume: (corresponding nominal amount)SEK 4 billion Highest permitted bid volume: (corr

AT&T and Nokia Drive Industry 4.0 with Private Networks Enabled by CBRS19.10.2020 15:10:00 CESTPress release

Press Release AT&T and Nokia drive Industry 4.0 with private networks enabled by CBRS 19 October 2020 Dallas, Texas - AT&T* has added Nokia’s end-to-end industrial-grade capabilities to its AT&T Private Cellular Networks solutions. Now businesses across the United States can build private networks through AT&T using Citizens Broadband Radio Service (CBRS) spectrum and Nokia infrastructure. Both Nokia Digital Automation Cloud and Modular Private Wireless platforms will be offered by AT&T. Private networks are increasingly important for businesses – especially in Industry 4.0 environments with a lot of connected devices, where privacy, data control and performance are all crucial. AT&T’s on-premises edge portfolio, which already includes 5G-capable AT&T Multi-Access Edge Computing (MEC), is expanding to offer these additional private cellular solutions with Nokia to meet those Industry 4.0 needs. This is a great solution for enterprise customers – including manufacturing, logistics, ener

NOVA Chemicals signs agreement to sell its expandable styrenics business to Alpek19.10.2020 15:00:10 CESTPress release

Refocuses on core olefin and polyethylene business; Strengthens balance sheet for continued growth and further investment in a plastics circular economy Pittsburgh, PA, Oct. 19, 2020 (GLOBE NEWSWIRE) -- NOVA Chemicals Corporation (“NOVA Chemicals”) today announced that it has agreed to sell its expandable styrenics business to a subsidiary of Alpek S.A.B. de C.V. (“Alpek”). The parties expect to close the transaction in the fourth quarter. The sale of its expandable styrenics business is an important step in NOVA Chemicals’ plan to focus on its olefin and polyethylene business, which includes additional investments to advance a global circular economy for plastic. “This transaction provides us with immediate cash generation to further strengthen our balance sheet and focus on the safe and successful completion and start-up of our, world-class Advanced SCLAIRTECH™ technology facility under construction in Ontario, Canada,” stated Luis Sierra, president and CEO of NOVA Chemicals. “I’d li